FemInEM
AdvocacySupport
Mifepristone safety requirements
Telehealth access to medication abortion
Telehealth prescribing
Citizen Petition from Attorney General of Massachusetts, et al.
FDA-2025-P-1576-0001Other
Comments
155
Last activity Jul 1, 2026
Deadline
--
Net supportiSupport minus oppose · campaigns included
-52%
-52% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Citizen Petition from Attorney General of Massachusetts, et al.
- Posted
- Jun 6, 2025
- Comment period
- Jun 6, 2025 – ?
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
-52%
Net support
Support36Oppose117Other2
Aggregates include form-letter campaigns. Excluding them, net support is -52% across organic comments.
Who commented
Breakdown by commenter type.
Academic
7
Business
2
Government
1
Individual
106
Advocacy
37
Other
2
Comments over time
Weekly arrivals, stacked by stance.
Posted Jun 6, 2025
Jul 21Aug 11Sep 1Oct 20Nov 17Feb 16Jun 29
Support36Oppose117Other2
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
14%
84%
2%
Advocacy
32%
68%
0%
Academic
100%
0%
0%
Business
100%
0%
0%
Other
0%
100%
0%
Government
0%
100%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Mifepristone safety requirements | Telehealth access to medication abortion | Telehealth prescribing | Environmental impact of mifepristone | Impact on ipv survivors |
|---|---|---|---|---|---|
FemInEM AdvocacySupport FemInEM, a non-profit organization focused on reproductive healthcare in emergency departments, supports the petition to | · | · |
15 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Aug 26, 2025Comment from John NaughtonOpposeIndividualRead comment →
- Aug 19, 2025Comment from sherry farmerOpposeIndividualRead comment →
- Aug 18, 2025Comment from JENNIFER RYKERT-DEANOpposeAdvocacy
The National Right to Life Committee (NRLC) opposes the proposed action to remove REMS for mifepristone. They argue that the drug poses risks to women's safety and call for the FDA to instead restore in-person dispensing, reinstate full adverse event reporting, and eventually reverse the drug's approval.
Read comment → - Aug 18, 2025Comment from Bonita MentzerOpposeIndividualRead comment →
- Aug 7, 2025Comment from Marie HilliardOpposeAdvocacy📎 Attachment
The Catholic Medical Association (CMA) opposes the petition to reduce or eliminate FDA safety regulations (REMS and EASU) for mifepristone. They argue that the petition relies on biased data that underestimates serious adverse effects and that removing these safeguards would exacerbate ethical and societal harms associated with telemedicine chemical abortions.
Read comment → - Jul 22, 2025Comment from AnonymousSupportIndividualRead comment →